A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/39 (2006.01)
Patent
CA 2662921
Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
L'invention concerne des compositions et des procédés, comprenant des vaccins et des compositions pharmaceutiques pour induire et améliorer une réponse immunitaire, sur la base de la découverte de propriétés d'adjuvant immunologique utiles chez un adjuvant lipidique synthétique de glucopyranosyle (GLA) qui est fourni sous une forme essentiellement homogène. Du point de vue de la définition chimique, le GLA synthétique offre un composant de vaccin régulier d'un lot à un autre sans les fluctuations de contaminants ou d'activité qui compromettent les adjuvants issus de produits naturels. Des vaccins et des compositions pharmaceutiques, qui comprennent du GLA et un ou plusieurs antigènes, un agoniste de récepteur de type Toll (TLR), un co-adjuvant et un support tel qu'un support pharmaceutique, sont également divulgués.
Carter Darrick
Reed Steven G.
Borden Ladner Gervais Llp
Infectious Disease Research Institute
LandOfFree
Vaccine composition containing synthetic adjuvant does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaccine composition containing synthetic adjuvant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine composition containing synthetic adjuvant will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1396433